Prostate Specific Antigen (PSA) Test Market Report 2026

The prostate specific antigen (psa) test market size has grown rapidly in recent years. It will grow from $4.65 billion in 2025 to $5.19 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing use of psa testing in clinical practice, expansion of laboratory diagnostic services, rising awareness of prostate cancer screening, availability of immunoassay-based test kits, integration of psa testing into routine checkups.

The prostate specific antigen (psa) test market size is expected to see rapid growth in the next few years. It will grow to $8.17 billion in 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to advancement of high-precision psa assay technologies, growing adoption of decentralized diagnostic testing, expansion of preventive cancer screening initiatives, increasing investments in diagnostic automation, rising demand for cost-effective screening solutions. Major trends in the forecast period include increasing adoption of routine psa screening programs, rising demand for point-of-care psa testing, growing use of high-sensitivity immunoassays, expansion of post-treatment monitoring applications, enhanced focus on early cancer detection.

The rising prevalence of prostate cancer is expected to drive the growth of the prostate-specific antigen (PSA) test market in the coming years. Prostate cancer develops when malignant cells form in the prostate gland, which is part of the male reproductive system. The prostate-specific antigen test is widely used as a screening method for prostate cancer in men, as it measures PSA levels in the blood and supports early detection and risk evaluation. For instance, in March 2023, according to reports published by the American Society of Clinical Oncology, a US-based professional organization for oncology specialists, an estimated 288,300 men in the United States were diagnosed with prostate cancer, and approximately 34,700 deaths were recorded in 2023. Therefore, the increasing prevalence of prostate cancer is fueling the growth of the prostate-specific antigen test market.

Major companies operating in the prostate-specific antigen test market are emphasizing product innovation and new launches, such as home-based PSA testing kits, to maintain their competitive position. Home testing kits are self-administered diagnostic tools that enable individuals to collect samples, conduct tests, and obtain results without visiting a healthcare facility. For instance, in September 2023, Randox, an Ireland-based health and toxicology company, introduced an at-home prostate-specific antigen testing kit. This PSA home test measures PSA levels in the blood to indicate potential abnormalities in the prostate. PSA is a protein produced by prostate gland cells, and elevated levels may signal conditions such as prostate enlargement, prostatitis, urinary tract infections, or the possible presence of prostate cancer.

In June 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to strengthen its advanced radioconjugate technology capabilities to support more targeted cancer treatments. Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage oncology company involved in the development of prostate-specific antigen-related diagnostic solutions.

Major companies operating in the prostate specific antigen (psa) test market are Siemens AG, F Hoffmann La Roche AG, Abbott Laboratories, Becton Dickinson And Company, PerkinElmer Inc, Beckman Coulter Inc, Bio Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, DiaSorin SpA, OPKO Health Inc, R And D Systems Inc, Meso Scale Diagnostics LLC, Tosoh America Inc, Fujirebio Europe NV, Boditech Med Inc, DRG International Inc, Enzo Life Sciences Inc, RayBiotech Inc, Novus Biologicals LLC, Creative Diagnostics Inc, Elabscience, LifeSpan BioSciences Inc, Accuquik Inc.

North America was the largest region in the prostate specific antigen (PSA) test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate specific antigen (psa) test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prostate specific antigen (psa) test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the prostate specific antigen test market by increasing costs of imported assay kits, reagents, analyzers, and laboratory consumables used in PSA testing workflows. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported immunoassay components, while Asia-Pacific faces higher costs in test kit manufacturing and distribution. These tariffs raise diagnostic expenses and affect test accessibility in some regions. However, they are also promoting local production of assay kits, regional reagent manufacturing, and greater investment in domestic diagnostic testing infrastructure.

The prostate specific antigen (psa) test market research report is one of a series of new reports that provides prostate specific antigen (psa) test market statistics, including prostate specific antigen (psa) test industry global market size, regional shares, competitors with a prostate specific antigen (psa) test market share, detailed prostate specific antigen (psa) test market segments, market trends and opportunities, and any further data you may need to thrive in the prostate specific antigen (psa) test industry. This prostate specific antigen (psa) test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate-specific antigen (PSA) test is a blood-based diagnostic test that measures the level of prostate-specific antigen present in the body. It is primarily used for the screening and ongoing monitoring of prostate cancer in men by evaluating the concentration of prostate-specific antigen in the bloodstream.

The primary types of prostate-specific antigen tests include clinical laboratory improvement amendments (CLIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), and others. Clinical laboratory improvement amendments refer to a set of regulations that oversee laboratory testing and require clinical laboratories to obtain certification from the Centers for Medicare and Medicaid Services before handling human samples for diagnostic purposes. These tests are used across multiple applications such as screening and post-treatment monitoring, and are utilized by end users including hospitals, diagnostic centers, research institutes, and others.

The prostate-specific antigen (PSA) test market includes revenues earned by entities by providing services such as prostate cancer detection, monitoring, PSA screening, prostatitis evaluation, complex PSA tests, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.